MASITINIB MESYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H30N6OS.CH4O3S
Molecular Weight	594.748
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CN1CCN(CC2=CC=C(C=C2)C(=O)NC3=CC(NC4=NC(=CS4)C5=CN=CC=C5)=C(C)C=C3)CC1

InChI

InChIKey=TXCWBWKVIZGWEQ-UHFFFAOYSA-N

InChI=1S/C28H30N6OS.CH4O3S/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34;1-5(2,3)4/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32);1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula	C28H30N6OS
Molecular Weight	498.642
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ab-science.com/en/corporate-overview/about-masitinib | http://www.ab-science.com/en/human-medicine/masitinib-in-neurodegenerative-disease | http://www.alzforum.org/therapeutics/masitinib

Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases. AB Science is developing masitinib in multiple sclerosis and alzheimer's disease. Masitinib targets kinases, including c-Kit, PDGFR, and Lyn. It is used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Stem cell growth factor receptor 57 Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626	Inhibitor 8504	200.0 nM [IC50]
Platelet-derived growth factor receptor alpha 33 Target ID: CHEMBL2007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626	Inhibitor 8504	540.0 nM [IC50]
Platelet-derived growth factor receptor beta 56 Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626	Inhibitor 8504	800.0 nM [IC50]
Tyrosine-protein kinase Lyn 4 Target ID: CHEMBL3905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19789626	Inhibitor 8504	510.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Amyotrophic lateral sclerosis 39 Sources: http://adisinsight.springer.com/drugs/800029638 https://www.ncbi.nlm.nih.gov/pubmed/27400786	Primary	Phase III 665	Unknown Approved Use Unknown
Mastocytosis 6 Sources: http://adisinsight.springer.com/drugs/800029638 https://www.ncbi.nlm.nih.gov/pubmed/28069279	Primary	Phase III 665	Unknown Approved Use Unknown
Alzheimer’s disease 278 Sources: http://adisinsight.springer.com/drugs/800029638 http://www.ab-science.com/en/human-medicine/masitinib-in-neurodegenerative-disease	Primary	Phase III 665	Unknown Approved Use Unknown
Multiple sclerosis 107 Sources: http://adisinsight.springer.com/drugs/800029638 http://www.ab-science.com/en/human-medicine/masitinib-in-neurodegenerative-disease	Primary	Phase III 665	Unknown Approved Use Unknown
Asthma 244 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT01449162	Primary	Phase III 665	Unknown Approved Use Unknown
Colorectal cancer 102 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT02605044	Primary	Phase III 665	Unknown Approved Use Unknown
Gastrointestinal stromal tumor 20 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT01694277	Primary	Phase III 665	Unknown Approved Use Unknown
Malignant melanoma 22 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT01280565	Primary	Phase III 665	Unknown Approved Use Unknown
Multiple myeloma 159 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT01470131	Primary	Phase III 665	Unknown Approved Use Unknown
Pancreatic cancer 98 Sources: http://adisinsight.springer.com/drugs/800029638 https://clinicaltrials.gov/ct2/show/NCT00789633	Primary	Phase III 665	Unknown Approved Use Unknown
Rheumatoid arthritis 320 Sources: https://clinicaltrials.gov/ct2/show/NCT01410695	Primary	Phase III 665	Unknown Approved Use Unknown
Dog mast cell tumours 2 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/000128/WC500064717.pdf	Primary	Approved 8583	Masivet Approved Use Treatment of non-resectable dog mast cell tumours (Grade 2 or 3) with confirmed mutated c-kit tyrosine kinase receptor. Launch Date 2008

Doses

Dose	Population	Adverse events
16 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 16 mg/kg, 1 times / day Route: oral Route: multiple Dose: 16 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/	DLT: Dehydration, Hyperbilirubinaemia... Dose limiting toxicities: Dehydration (grade 4) Hyperbilirubinaemia (grade 3) Renal insufficiency (grade 4) Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/

AEs

AE	Significance	Dose	Population
Hyperbilirubinaemia	grade 3 DLT	16 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 16 mg/kg, 1 times / day Route: oral Route: multiple Dose: 16 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/
Dehydration	grade 4 DLT	16 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 16 mg/kg, 1 times / day Route: oral Route: multiple Dose: 16 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/
Renal insufficiency	grade 4 DLT	16 mg/kg 1 times / day multiple, oral Highest studied dose Dose: 16 mg/kg, 1 times / day Route: oral Route: multiple Dose: 16 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/19541476/

PubMed

Title	Date	PubMed
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.	2013-04-15	23398362
Comprehensive analysis of kinase inhibitor selectivity.	2011-10-30	22037378
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.	2011-10-30	22037377
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.	2010-12	21108325
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.	2010-11-24	21095574
Clinical trial on the efficacy of masitinib in canine IBD.	2010-11-06	21257519
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.	2010-11	21034327
Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11.	2010-10-15	20950418
Churg and Strauss vasculitis in the course of masitinib treatment: a first report.	2010-08	19958320
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.	2010-07	20364428
[Focus on GIST management].	2010-06	20483709
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).	2010-05	20211560
The complexity of the complicity of mast cells in cancer.	2010-05	20026421
"Masitinib" is safe and effective for the treatment of canine mast cell tumors.	2010-04-15	20391634
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.	2010-03-04	20209107
Drug-induced minimal change nephropathy in a dog.	2010-02-09	20136717
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.	2010-02-04	20161982
Masitinib for the treatment of canine atopic dermatitis: a pilot study.	2010-01	20033487
[New drugs for small animals in 2009].	2010	22215315
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.	2010	20181277
Pharmacokinetics of masitinib in cats.	2009-12	19533403
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.	2009-09-30	19789626
Clinically relevant advances in rheumatoid arthritis therapy.	2009-09-14	20948712
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.	2009-09	19541476
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.	2009-08	19614621
More about masitinib.	2009	19664170
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.	2009	19549290
Masitinib is safe and effective for the treatment of canine mast cell tumors.	2008-10-01	18823406
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].	2008-01	18230576

Patents

Sample Use Guides

In Vivo Use Guide

6 mg/kg/day

Route of Administration: Oral

In Vitro Use Guide

In Ba/F3 cells expressing human wild-type Kit, Masitinib inhibits SCF (stem cell factor)-induced cell proliferation with an IC50 of 150 nM, while the IC50 for inhibition of IL-3-stimulated proliferation is at approximately >10 µM. In Ba/F3 cells expressing PDGFRα, Masitinib inhibits PDGF-BB-stimulated proliferation and PDGFRα tyrosine phosphorylation with IC50 of 300 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:45:14 GMT 2025` Edited by `admin` on `Mon Mar 31 18:45:14 GMT 2025`
Record UNII	ZK89EG3A18
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MASITINIB MESILATE

Preferred Name

English

MASITINIB MESYLATE

Common Name

English

4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE METHANESULPHONATE

Systematic Name

English

4-((4-METHYLPIPERAZIN-1-YL)METHYL)-N-(4-METHYL-3-((4-PYRIDIN-3-YL-1,3-THIAZOL-2-YL)AMINO)PHENYL)BENZAMIDE METHANESULFONATE

Systematic Name

English

Masitinib mesilate [WHO-DD]

Common Name

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-THIAZOLYL)AMINO)PHENYL)-, METHANESULFONATE (1:1)

Systematic Name

English

AB-1010

Code

English

BENZAMIDE, 4-((4-METHYL-1-PIPERAZINYL)METHYL)-N-(4-METHYL-3-((4-(3-PYRIDINYL)-2-THIAZOLYL)AMINO)PHENYL)-, METHANESULPHONATE (1:1)

Systematic Name

English

MASIVIERA

Brand Name

English

MASITINIB METHANESULFONATE [MI]

Common Name

English

AB1010

Code

English

MASIVET

Brand Name

English

MASITINIB MESYLATE [EMA EPAR VETERINARY]

Common Name

English

MASICAN

Brand Name

English

MASITINIB MESYLATE [GREEN BOOK]

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

MASICAN (REFUSED: GASTROINTESTINAL STROMAL TUMORS)